TEV-53275 for Asthma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a new treatment, TEV-53275, can relieve asthma symptoms in adults with ongoing asthma involving eosinophils, a type of white blood cell. Researchers will compare TEV-53275 to a placebo (a harmless pill with no active drug) to assess its effects on lung function, asthma symptoms, and quality of life. The trial will also evaluate the treatment's safety and any unusual body reactions. It suits adults who have had asthma for at least six months and have remained stable on their current asthma medications without flare-ups for the past month. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial protocol does not specify that you need to stop taking your current asthma medications. In fact, it mentions that participants should be able to continue their current asthma maintenance medications throughout the study.
Is there any evidence suggesting that TEV-53275 is likely to be safe for humans?
Research has shown that TEV-53275, a new treatment tested for asthma, presents some safety concerns. Most side effects observed in studies were mild or moderate, with headaches being the most common. However, a few participants experienced serious side effects, including severe headaches. While many people tolerate the treatment well, some may face risks. Anyone considering joining a trial should discuss these potential side effects with their doctor.12345
Why do researchers think this study treatment might be promising for asthma?
Unlike traditional asthma treatments like inhaled corticosteroids and bronchodilators, TEV-53275 is unique because it introduces a new approach by targeting specific pathways involved in asthma's inflammatory process. Researchers are excited about TEV-53275 because it may offer more precise control over asthma symptoms with potentially fewer side effects. The treatment comes in two experimental doses, Dose A and Dose B, allowing researchers to evaluate the most effective dose for relief. This novel approach could mean faster symptom relief and improved quality of life for asthma patients.
What evidence suggests that TEV-53275 might be an effective treatment for persistent asthma?
Research has shown that TEV-53275 may benefit individuals with a type of asthma that doesn't respond well to regular treatments. In earlier studies, patients who received TEV-53275 experienced better lung function and fewer asthma symptoms compared to those who received a placebo (a harmless, inactive substance). These studies also found that patients required less rescue medication, used when asthma symptoms suddenly worsen. In this trial, participants will receive either TEV-53275 at different doses or a placebo. The treatment is administered as an injection under the skin and is being tested for its safety and tolerability. Overall, early results suggest that TEV-53275 could be a promising option for managing persistent asthma involving certain white blood cells.12346
Who Is on the Research Team?
Teva Medical Expert, MD
Principal Investigator
Teva Branded Pharmaceutical Products R&D, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Run-in
Participants undergo a 2-week run-in period to stabilize their condition before treatment
Treatment
Participants receive TEV-53275 or placebo subcutaneously for 16 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- TEV-53275
Find a Clinic Near You
Who Is Running the Clinical Trial?
Teva Branded Pharmaceutical Products R&D, Inc.
Lead Sponsor
Dr. Eric Hughes
Teva Branded Pharmaceutical Products R&D, Inc.
Chief Medical Officer since 2022
MD and PhD from Yale School of Medicine
Richard Francis
Teva Branded Pharmaceutical Products R&D, Inc.
Chief Executive Officer since 2022
Bachelor's degree in Biochemistry from the University of Manchester